QM · rank #16 · 2026-10-21
IBRX
NASDAQ · $8.92B (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +209.52% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +0.0% |
| Profit margin Net profit margin, trailing 12 months. | +0.0% |
| Market cap (USD) Size filter: > $500M required. | $8.92B |
| Anchor (recent) Close on 2026-09-21 | $8.45 |
| Anchor (far) Close on 2025-09-19 | $2.73 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
ImmunityBio is a commercial-stage biopharmaceutical company developing and commercializing ANKTIVA, an IL-15 receptor agonist paired with BCG for non-muscle-invasive bladder cancer and broader oncology settings.
Rationale
The strong 12-month price momentum signal (2.0952) is fundamentally backed by eight consecutive quarters of sequential product revenue growth ($50.7M in Q2 2026) and the FDA's October 2026 label expansion into papillary-only BCG-unresponsive NMIBC.
Material risks
- 1High operating cash burn ($141.9M in H1 2026) creates significant dilution risk via potential equity offerings before ANKTIVA sales achieve operating cash-flow breakeven.
- 2Competitive displacement by alternative bladder-preserving treatments like Johnson & Johnson’s Inlexzo/TAR-200 and dependence on reliable contract manufacturing and BCG supply chains.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.